Information Notice No. 95-39: Brachytherapy Incidents Involving Treatment Planning Errors
UNITED STATES
NUCLEAR REGULATORY COMMISSION
OFFICE OF NUCLEAR MATERIAL SAFETY AND SAFEGUARDS
WASHINGTON, D.C. 20555-0001
September 19, 1995
NRC INFORMATION NOTICE 95-39: BRACHYTHERAPY INCIDENTS INVOLVING TREATMENT
PLANNING ERRORS
Addressees
All U.S. Nuclear Regulatory Commission Medical Licensees.
Purpose
The U.S. Nuclear Regulatory Commission (NRC) is issuing this information
notice to alert addressees to brachytherapy incidents involving treatment
planning errors. It is expected that recipients will review the information
for applicability to their facilities and consider actions, as appropriate, to
avoid similar problems. However, suggestions contained in this information
notice are not new NRC requirements; therefore, no specific action nor written
response is required.
Description of Circumstances
NRC has become aware of the following brachytherapy incidents related to
treatment planning errors:
1) On November 21, 1994, an NRC licensee discovered that an error had
occurred during the programming of a high-dose-rate (HDR) Gamma Med II-i
brachytherapy device on November 18, 1994. While programming treatment
data into the HDR unit, the technologist failed to press the AUTOMATIC
TIME FACTOR button. After entering the dwell positions and the total
treatment time, the technologist attempted to start the treatment by
pressing the START and SOURCE IN IRRAD. POS. buttons. The HDR unit
displayed an error message on the screen indicating the need for MANUAL
TIME FACTOR. The technologist interpreted this to mean that the
computer had not received the total treatment time data and reentered
the data. The total treatment time data were inadvertently used as the
MANUAL TIME FACTOR, resulting in the administration of approximately
twice the intended radiation dose. The failure of the technologist to
press the AUTOMATIC TIME FACTOR button, during initial entry of the
treatment data, was exacerbated by an apparent defect, in the GAMUHR
card, that permitted the technologist to manually enter and accept the
inappropriate decay factor during the programming process. The device
contained a nominal 370-giga becquerel (GBq) (10-curie (Ci)) iridium-192
sealed source. As a result, the patient received a dose of 12 Gray (Gy)
(1200 rad) to the vaginal cavity instead of the prescribed dose of 6 Gy
(600 rad).
2) On September 23, 1994, a licensee informed Region III that a patient
undergoing a uterine brachytherapy implant received a 31 percent
9509130018. IN 95-39
September 19, 1995
Page 2 of 4
underdose. On September 13, 1994, the patient was implanted with two
cesium-137 (Cs-137) brachytherapy sources, in an ovoid applicator, to
deliver 65 Gy (6500 rad) to the uterine lining, in approximately
48 hours. During review of the completed treatment, the licensee's
medical physicist determined that the wrong tissue volume was used
during the treatment planning process, resulting in a smaller volume
being treated than the administering physician intended. Although the
physician reviewed and approved the treatment plan before
administration, it was not apparent that a smaller tissue volume was
represented in the plan. The licensee believes that the dosimetrist who
prepared the treatment plan used incorrect spatial coordinates to define
the treatment volume and failed to verify the dose calculations. The
licensee determined that the treatment of the smaller volume resulted in
the delivery of 45 Gy (4500 rad) to the intended treatment volume, which
was a 31 percent underdose. To compensate for the 20 Gy (2000 rad)
underdose, the administering physician modified a previously intended
boost dose, using external beam therapy (via a linear accelerator).
3) An Agreement State licensee reported an event in which an incorrect dose
conversion factor was used for planning a treatment. One patient was
treated with three Cs-137 seeds during a gynecological implant procedure
during the period of May 4-8, 1994. The patient received approximately
91.3 Gy (9130 rad) to the treatment area, which was about 283 percent
greater than prescribed. Further investigation revealed that the error
involved six additional patients, with the patients receiving doses from
37 percent to 144 percent in excess of their intended doses. The
calculation error was caused when the physicist entered the wrong gamma
constant when editing the treatment planning program. The physicist was
attempting to convert from �milligram radium equivalent� to �millicurie�
and entered 3.256 �radium� instead of �millicurie,� resulting in an
error ratio that was 2.5 times greater than expected.
4) On April 8, 1994, an NRC licensee reported an incident involving a data
entry error in the treatment planning process. The written directive
specified two fractions of 6 Gy (600 rad) per fraction for a total dose
of 12 Gy (1200 rad). Before the first treatment, a radiation therapist
correctly entered the treatment parameters into the GammaMed II-i HDR.
A second radiation therapist and the radiation physicist verified that
this entry of data was correct. The GammaMed II-i HDR device used the
European date format (day-month-year) for this parameter. At the time
of the treatment, the radiation therapist recalled the correct treatment
parameters from the computer memory, but inadvertently entered the
treatment date in the incorrect format (i.e., 4.06.94 instead of
6.04.94). Because the HDR computer automatically adjusts for source
decay, the exposure time was modified by a factor of 3.17 (for June 4)
instead of the required modifying factor of 1.83 (for April 6). This
resulted in an administered fractional dose of 10.39 Gy (1039 rad)
instead of the intended prescribed 6 Gy (600 rad). However, the total
prescribed dose of 12 Gy (1200 rad) was not exceeded because the error
was detected before the second treatment was administered.. IN 95-39
September 19, 1995
Page 3 of 4
5) On October 11, 1993, an NRC licensee reported a therapeutic
misadministration, discovered during a routine review of records, that
occurred on April 23, 1993, during a brachytherapy procedure involving a
high-dose-rate (HDR) remote afterloader. According to the medical
physicist, a patient was scheduled to receive vaginal brachytherapy
treatment using a Nucletron HDR unit with a 157.14 GBq (4.247 Ci)
iridium-192 source. The prescribed dose for the fraction was 5 Gy
(500 rad). During the planning of the second of the three treatments,
an error was made in the input of the offset distance. Instead of
992 millimeter (mm), a distance of 920 mm was entered. The source was
programmed to travel 45 mm outward from the offset distance in nine
increments of 5 mm each. The medical physicist indicated that the
treatment progressed as was planned. However, because of the erroneous
input for the offset distance, a portion of the dose was administered to
the wrong site.
6) On August 18, 1993, a therapeutic misadministration occurred at a
licensee's facility when a patient who was scheduled to receive a 6 Gy
(600 rad) dose of radiation to his esophagus actually received a 10 Gy
(1000 rad) dose. The licensee identified the error during a routine
physics check conducted that same day. The licensee indicated that a
treatment plan was developed to deliver the 6 Gy (600 rad) dose and that
this plan was reviewed by the physicist and physician and found to be
correct. However, before administering the dose, the physicist
reaccessed the HDR treatment planning system to modify a noncritical
factor. The physicist reported having a problem maneuvering between the
various menus in the treatment planning system, which involved pressing
the �Esc� key several times. This caused the treatment planning program
to change the value of the treatment dose to 10 Gy (1000 rad).
According to the licensee, the modified plan was put into the HDR
control computer without an additional in-depth review and the treatment
was delivered.
Discussion
The incidents listed above demonstrate the importance of following plans and
procedures to meet the objective stated in 10 CFR 35.32(a)(3) that final
treatment plans and related calculations are in accordance with the written
directive. Attention to details in treatment planning and independent
verification of treatment plans may be involved in meeting this objective. If
independent verification of treatment plans is so relied upon, it should
include verification of the data used to calculate the initial treatment plan,
as well as the calculations. It is important to note that recalculation of
the treatment plan from the same data set used to prepare the initial
treatment may not catch errors introduced by initially inputting incorrect
treatment parameters. . IN 95-39
September 19, 1995
Page 4 of 4
This information notice requires no specific action nor written response. If
you have any questions about the information in this notice, please contact
the technical contact listed below, or the appropriate NRC regional office.
/s/'d by Larry W. Camper/for
Donald A. Cool, Director
Division of Industrial and
Medical Nuclear Safety
Office of Nuclear Material Safety
and Safeguards
Technical contact: James A. Smith, NMSS
(301) 415-7904
Page Last Reviewed/Updated Wednesday, March 24, 2021